[A21-124] Isatuximab (multiple myeloma after >= 2 prior therapies, combination with pomalidomide and dexamethasone) - Addendum to Commission A21-61

Last updated 04.11.2021

Project no.:
A21-124

Commission:
Commission awarded on 30.09.2021 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with relapsed and refractory multiple myeloma who have received ≥ 2 prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy

Result of dossier assessment:

Unchanged after addendum: Added benefit not proven

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Federal Joint Committee (G-BA)

04-11-2021 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form